首页> 外国专利> Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives

Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives

机译:取代的含吡啶基或嘧啶基的6,6-或6,7-双环芳基磺酰基氨基异羟肟酸衍生物

摘要

A compound of the formula I wherein; the dashed lines represent optional double bonds; A is nitrogen or CR7; B is -NR1R2, -CR1R2R10, -C(=CR2R11)R1, -NHCR1 R2Rl0, -OCR1R2R10, -SCR1R2R10, -CR2R10NHR1, -CR2Rl0ORl, -CR2R10SR' or -COR2, and is single bonded to D; or B is -CRR, and is double bonded to D and D is carbon; D is nitrogen or CR4 and is single bonded to all atoms to which it is attached, or D is carbon and is double bonded to E or double bonded to B; E is oxygen, nitrogen, sulfur, C=O, C=S, CR8R12, NRs or CR6; or E is a two atom spacer, wherein one of the atoms is oxygen, nitrogen, sulfur, C=O, C=S, CR6R12, NR6 or CR6, and the other is CR6R12 or CR9 K and G are each, independently, C=O, C=S, sulfur, oxygen, CHR8 or NR8 when single bonded to both adjacent ring atoms, or nitrogen or CR8 when it is double bonded to an adjacent ring atom; the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C=O or C=S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring; R1 is alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C1 -C4 alkoxy, CF3, -C(=O)(C1-C4alkyl), -C(= O)-O-(C1-C4)alkyl, -OC(= O)(C1-C4 alkyl), -OC(= O)N(C1-C4 alkyl)(C1-C2 alkyl), -NHCO(C1-C4 alkyl), -COOH, -COO(C1-C4 alkyl), -CONH(C1-C4 alkyl), -CON(C1-C4 alkyl)(Cl-C2 alkyl), -S(C1-C4 alkyl), -CN, -NO2, -SO(C1-C4 alkyl), -SO2(C1-C4 alkyl), -SO2NH(C1-C4 alkyl) and -SO2N(C1-C4 alkyl)(Cl-C2 alkyl), wherein each of the Cl -C4 alkyl groups in the foregoing R1 groups may optionally contain one or two double or triple bonds; R2 is C1 -C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1 -C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1 -C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C1-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1 -C6 alkylene)(C3-CB cycloalkyl may optionally and independently be replaced by an oxygen or sulfur and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from Cl-Ce alkoxy, -OC(=O)(C1-C6 alkyl), -OC(=O)N(Cl-C4 alkyl)(C,-C2 alkyl), -S(C1-C6 alkyl), amino, -NH(Cl-C2 alkyl), -N(C1-C2 alkyl)(C1-C4 alkyl), -N(C1-C4 alkyl)-CO-(C1-C4 alkyl), -NHCO(Cl-C4 alkyl), -COOH, -COO(Cl-C4 alkyl), -CONH(Ct-C4 alkyl), -CON(Cl-C4 alkyl)(C,-C2 alkyl), -SH, -CN, -NO2, -SO(C,-C4 alkyl), -SO2(C1-C4 alkyl), -SO2NH(C1-C4 alkyl) and -SO2N(C1-C4 alkyl)(Cl-C2 alkyl); -NR1R2 or CR1R2R10 may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ3 wherein Z3 is hydrogen or C1-C4 alkyl; R3 is hydrogen, C1-C4 alkyl, -O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, -S(C1-C4 alkyl) or -SO2(C1-C4 alkyl) R4 is hydrogen, C1-C2 alkyl, hydroxy or fluoro; each R6, R8 and R9 that is attached to a carbon atom is selected, independently, from hydrogen, Cl-C2 alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxymethyl, formyl, trifluoromethyl, cyano, amino, nitro, -O(C1-C2 alkyl), -N(C1-C2 alkyl)(C1-C2 alkyl), -S(C1-C2 alkyl), -CO(C1-C2 alkyl), -C(=O)H or -C(=O)O(C1-C2 alkyl), wherein each of the C1-C2 alkyl moieties in the foregoing R6, R8, and B9 groups may optionally contain one double or triple bond; and each R6, RB, and R9 that is attached to a nitrogen atom is selected, independently, from hydrogen and C1-C4 alkyl; R5 is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R5 groups is substituted with from two to four substituents R'5, wherein from one to three of said substituents may be selected, independently, from chloro, C1-C6 alkyl, -O(Cl-Ce alkyl) and -(C1-C6alkylene)O(C1-C8alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, -NH(C1 -C4 alkyl), -N(C1-C2 alkyl)(C1 -C6 alkyl), -C(=O)O(C1-C4 alkyl), -C(=O)(C1-C4 alkyl), -COOH, -S02NH(C,-C4 alkyl), -SO2N(C1-C2 alkyl)(Cl-C4 alkyl), -SO2NH2, -NHSO2(C1-C4 alkyl), -S(Cl-Ce alkyl) and -SO2(C1-C alkyl), and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally be substituted with one ortwo substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl; R7 is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, -C(=O)(C1-C2 alkyl), -C(=O)O(C1-C2 alkyl), trifluoromethoxy, hydroxymethyl, trifluoromethyl or formyl; R10 is hydrogen, hydroxy, methoxy or fluoro; R11 is hydrogen or C1-C4 alkyl; R12 is, hydrogen or methyl; and Z is NH, oxygen, sulfur, -N(C1-C4 alkyl), or CR'3R14 wherein R13 and R14 are independently selected from hydrogen, and methyl with the exception that one of R'3 and R14 may optionally be cyano; with the proviso that: (a) in the six or seven membered rings of structures in formula I, there can not be two double bonds adjacent to each other; and (b) when D is carbon and is double bonded to B, then B is CR1 R2; or a pharmaceutically acceptable salt of such compound. The compounds are useful for the treatment, prevention or inhibition of conditions effected or facilitated by antagonizing CRF.
机译:式I化合物,其中;虚线表示任选的双键; A是氮或CR 7; B是-NR1R2,-CR1R2R10,-C(= CR2R11)R1,-NHCR1 R2R10,-OCR1R2R10,-SCR1R2R10,-CR2R10NHR1,-CR2R10OR1,-CR2R10SR'或-COR2,并且与D单键结合;或B为-CRR,且与D双键且D为碳;或D是氮或CR 4,并且与它所连接的所有原子单键连接,或者D是碳,并且与E双键或与B双键连接; E为氧,氮,硫,C = O,C = S,CR8R12,NRs或CR6;或E为两个原子的间隔基,其中一个原子为氧,氮,硫,C = O,C = S,CR6R12,NR6或CR6,另一个为CR6R12或CR9。K和G分别独立地为C当与两个相邻的环原子单键结合时,= O,C = S,硫,氧,CHR8或NR8,或者与相邻的环原子双键结合时的氮或CR8。含有D,E,K和G的6元或7元环可以含有1至3个双键,0至2个选自氧,氮和硫的杂原子,以及0至2个C = O或C = S基团,其中这些基团的碳原子是环的一部分,氧和硫原子是环上的取代基; R1是任选地被一个或两个独立地选自羟基,氟,氯,溴,碘,碘,C1-C4烷氧基,CF3,-C(= O)(C1-C4烷基),-C(= O)-的取代基取代的烷基O-(C1-C4)烷基,-OC(= O)(C1-C4烷基),-OC(= O)N(C1-C4烷基)(C1-C2烷基),-NHCO(C1-C4烷基) ,-COOH,-COO(C1-C4烷基),-CONH(C1-C4烷基),-CON(C1-C4烷基)(C1-C2烷基),-S(C1-C4烷基),-CN,- NO 2,-SO(C 1 -C 4烷基),-SO 2(C 1 -C 4烷基),-SO 2 NH(C 1 -C 4烷基)和-SO 2 N(C 1 -C 4烷基)(C 1 -C 2烷基),其中每个Cl-前述R1基团中的C4烷基可任选地含有一个或两个双键或三键; R 2为C 1 -C 12烷基,其可任选地包含1-3个双键或三键,芳基或(C 1 -C 4亚烷基)芳基,其中所述芳基和所述(C 1 -C 4亚烷基)芳基的芳基部分选自苯基,萘基,噻吩基,苯并噻吩基,吡啶基,喹啉基,吡嗪基,嘧啶基,咪唑基,呋喃基,苯并呋喃基,苯并噻唑基,异噻唑基,吡唑基,吡咯基,吲哚基,吡咯并吡啶基,恶唑基和苯并恶唑基C 3 -C 8环烷基或(C 1 -C 6亚烷基)(C 3 -C 8环烷基),其中所述环烷基的碳原子中的一个或两个和所述(C 1 -C 6亚烷基)(C 3 -CB环烷基)的5至8元环烷基部分可以任选地和独立地被氧或硫取代,并且其中每个前述R 2基团可以任选地被1-3个独立地选自氯,氟,羟基和C1-C4烷基的取代基取代,或被一个选自Cl的取代基取代。 -Ce烷氧基,-OC(= O)(C1-C6烷基),-OC(= O)N(C1-C4烷基)(C,-C2烷基),-S(C1-C6烷基),氨基,- NH(C1-C2烷基),-N(C1-C2烷基)(C1-C4烷基),-N(C1-C4烷基)-CO-(C1-C4烷基),-NHCO(C1-C4烷基), -COOH,-COO(C1-C4烷基),-CONH(Ct-C4烷基),-CON(C1-C4烷基)(C,-C2烷基),-SH,-CN,-NO2,-SO(C -C4烷基),-SO2(C1-C4烷基),-SO2NH(C1-C4烷基)和-SO2N(C1-C4烷基)(C1-C2烷基);-NR1R2或CR1R2R10可形成选自饱和的环3至8元环,其中5至8元环可以选择1ly含有一个或两个双键,并且其中5至8元环的一个或两个环碳原子可以任选地和独立地被氧或硫原子或被Z 3为氢或C 1 -C 4烷基的NZ 3取代; R 3是氢,C 1 -C 4烷基,-O(C 1 -C 4烷基),氯,氟,溴,碘,-S(C 1 -C 4烷基)或-SO 2(C 1 -C 4烷基)R 4是氢,C 1 -C 2烷基,羟基或氟;连接至碳原子的每个R 6,R 8和R 9独立地选自氢,C 1 -C 2烷基,氟,氯,溴,碘,羟基,羟甲基,甲酰基,三氟甲基,氰基,氨基,硝基,-O (C1-C2烷基),-N(C1-C2烷基)(C1-C2烷基),-S(C1-C2烷基),-CO(C1-C2烷基),-C(= O)H或-C (= O)O(C 1 -C 2烷基),其中上述R 6,R 8和B 9基团中的每个C 1 -C 2烷基部分可任选地包含一个双键或三键;且与氮原子连接的R 6,RB和R 9各自独立地选自氢和C 1 -C 4烷基。 R5是取代的苯基,萘基,吡啶基或嘧啶基,其中上述每个R5基团被2-4个取代基R'5取代,其中1-3个所述取代基可独立地选自氯,C1-C6烷基,-O(C 1 -C 6烷基)和-(C 1 -C 6亚烷基)O(C 1 -C 8烷基),其中所述取代基之一可以独立地选自溴,碘,甲酰基,氰基,三氟甲基,硝基,氨基,-NH(C1-C4烷基),-N(C1-C2烷基)(C1-C6烷基),-C(= O)O(C1-C4烷基),-C(= O)(C1-C4烷基) ),-COOH,-SO 2 NH(C 1 -C 4烷基),-SO 2 N(C 1 -C 2烷基)(C 1 -C 4烷基),-SO 2 NH 2,-NHSO 2(C 1 -C 4烷基),-S(C 1 -C 6烷基)和-SO2(C1-C烷基)且其中前述R 5基团中的每个C 1 -C 4烷基和C 1 -C 6烷基部分可任选地被一个或两个独立地选自氟,羟基,氨基,甲基氨基,二甲基氨基和乙酰基的取代基取代; R7为氢,甲基,卤素(例如氯,氟,碘或溴),羟基,甲氧基,-C(= O)(C1-C2烷基),-C(= O)O(C1-C2烷基),三氟甲氧基,羟甲基,三氟甲基或甲酰基; R10是氢,羟基,甲氧基或氟; R11是氢或C1-C4烷基; R12是氢或甲基; Z是NH,氧,硫,-N(C 1 -C 4烷基)或CR′3 R 14,其中R 13和R 14独立地选自氢,和甲基,但R′3和R 14之一可以任选地是氰基。前提是:(a)在式I的六或七个成员环中,不能有两个彼此相邻的双键; (b)当D为碳且与B双键时,则B为CR1 R2;或此类化合物的可药用盐。该化合物可用于治疗,预防或抑制拮抗CRF而引起或促进的疾病。

著录项

  • 公开/公告号NZ333727A

    专利类型

  • 公开/公告日2000-09-29

    原文格式PDF

  • 申请/专利权人 PFIZER INC;

    申请/专利号NZ19970333727

  • 发明设计人 CHEN YUHPYNG LIANG;

    申请日1997-07-23

  • 分类号A61K31/44;C07D471/04;A61K31/505;

  • 国家 NZ

  • 入库时间 2022-08-22 01:55:27

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号